Recruiting
A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Ninetedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants - IM027-1026
Atualizado: 29 outubro, 2024 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Localização(ões)
Recruiting
Inclusion Criteria: - Participants must be healthy males and females (INOCBP) - Participant must have Body mass index (BMI) of 18.0 kg/m2 through 32.0 kg/m2, inclusive. - Participant must have Body weight ≥ 50 kg Exclusion Criteria: - Participant must not have current or recent GI disease - Participant with evidence of organ dysfunction or any clinically significant deviation, as determined by investigator, from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population. - Participant with prior exposure to BMS-986278 and exposure of any investigational drug or placebo within 4 weeks of study intervention administration. - Other protocol-defined Inclusion/Exclusion criteria apply.
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
